Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates
The maternal healthcare market in India is witnessing remarkable growth and consolidation. Consequently, global private equity giants are competing to acquire a substantial stake in Cloudnine Hospitals. This major transaction could value the premier maternity and pediatric chain at approximately ₹11,000 crore. Additionally, existing investor True North plans to completely exit its 25% holding.
Furthermore, this investment wave highlights the rising confidence in specialized healthcare delivery. Historically, early investors like Matrix Partners and Sequoia Capital backed the Bengaluru-based company. Subsequently, Singapore's Temasek and TPG NewQuest acquired significant stakes. Together, they currently hold about 52% of the entity.
Indeed, Cloudnine recently finalized a transformative acquisition to strengthen its market position. The chain acquired a 90% stake in Apollo Cradle and Apollo Fertility for ₹1,550 crore. Therefore, the combined network will now operate over 55 clinical centers across India. This merger creates a highly integrated platform for women's healthcare, obstetrics, and neonatology. Moreover, the expanding maternal healthcare market is projected to grow at a compound annual rate of 15%.
Meanwhile, Cloudnine reported impressive revenues of nearly ₹2,000 crore for the fiscal year 2025-26. The organization also recorded EBITDA of approximately ₹300 crore during this period. However, volatile conditions previously forced the company to defer its ₹1,200 crore initial public offering. Fortunately, fresh capital from incoming private equity partners will fuel their upcoming expansion goals. Ultimately, this consolidation trend signals a major shift toward high-quality, organized clinical care across the nation.
Q1: What is the current valuation of Cloudnine in the proposed stake sale?
The proposed transaction values Cloudnine at approximately ₹11,000 crore, attracting major global private equity firms.
Q2: How does the recent Apollo Cradle merger affect Cloudnine?
The ₹1,550 crore acquisition adds Apollo Cradle and Apollo Fertility to Cloudnine, expanding the combined network to over 55 centers nationwide.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Link will be sent via SMS to your number.
Cloudnine Healthcare is attracting global private equity interest for a 25% stake sale valuing the company at ₹11,000 crore. This development follows its major ₹1,550 crore acquisition of Apollo Cradle, marking a rapid consolidation in India's maternal and child healthcare sector.
2 days back
A recent study reveals that PYCR1 drives osteosarcoma proliferation by activating the PI3K/Akt signaling pathway and inhibiting ferroptosis. These findings highlight PYCR1 as a critical metabolic regulator and a potential therapeutic target for treating drug-resistant and metastatic bone cancer.
Today
A large-scale retrospective study reveals a sharp rise in gestational and type 2 diabetes alongside severe maternal morbidity between 2016 and 2022. While gestational diabetes is most prevalent, type 1 diabetes poses the highest risk for maternal complications, necessitating multidisciplinary care.
Today
AI is transforming pediatric radiology by enhancing diagnostic accuracy in neuroimaging, cardiovascular care, and oncology. This primer explores the current landscape of pediatric-specific AI tools, highlighting benefits like automated bone age assessment and the critical need for child-centered validation.
Today
Researchers developed a pose-aware deep perceptual metric using contrastive learning to improve 2D/3D registration of knee joints. This AI-driven approach enhances capture range, robustness to noise, and accuracy in joint kinematics analysis for orthopedic procedures.
Today
A target trial emulation study within the Veterans Health Administration shows that starting CGM therapy is associated with a 10% to 16% reduction in all-cause mortality for older-onset type 1 diabetes patients, particularly those over 65 or not using insulin pumps.
Today